The looming polypharmacy crisis in the management of patients with heart failure: Potential solutions

Cardiology Clinics

Volumn 19, Issue 4, 2001, Pages 541-545

  Francis, Gary S ^a,c   Young, James B ^b,c  

^a Pediatric Intensive Care Unit   (United States)

^b Section of Heart Failure   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

DNA POLYMORPHISM; HEART FAILURE; HUMAN; MEDICAL DECISION MAKING; PATIENT CARE; POLYPHARMACY; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW;

EID: 0034766938     PISSN: 07338651     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0733-8651(05)70241-1     Document Type: Review

References (33)

1. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure
2. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction
3. The cardiac insufficiency bisoprolol study II (CIBIS-II): A randomized trial
4. Pharmacogenics: Hope or hype?
5. Effect of vasodilator therapy on mortality in chronic congestive heart failure
6. Effects of enalapril on mortality in severe congestive heart failure
7. Angiotensin-converting enzyme in the human heart
8. aq a novel target for heart failure?
9. The heart outcomes prevention evaluation Study investigators: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients
10. Survival after the onset of congestive heart failure in Framingham heart study subjects
11. β2-Adrenergic receptor polymorphisms at amino acid 16 differentially influence agonist-stimulated blood pressure and peripheral blood flow in normal individuals
12. Epidemiology of heart failure
13. Changing epidemiological features of cardiac failure
14. Absence of association or genetic linkage between the angiotensin-converting enzyme gene and left ventricular mass
15. Evolving trends in the epidemiologic factors of heart failure: Rationale for preventive strategies and comprehensive disease management
16. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF)
17. Symptomatic and symptomatic left-ventricular systolic dysfunction in an urban population
18. Biochemical detection of left-ventricular systolic dysfunction
19. A polymorphisms display different sensitivities to agonists
20. Angiotensin-converting-enzyme gene insertion/deletion polymorphism and response to physical training
21. Lack of association between the insertion/deletion polymorphism of the angiotensin-converting enzyme gene and idiopathic dilated cardiomyopathy
22. Association of two silent polymorphisms of platelet glycoprotein Ia/IIa receptor with risk of myocardial infarction: A case-control study
23. The genotype of the angiotensin-converting enzyme gene and global left ventricular dysfunction after myocardial infarction
24. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure
25. The effect of spironolactone on morbidity and mortality in patients with severe heart failure
26. A1/A2 polymorphism of platelet glycoprotein Ha and risks of myocardial infarction, stroke, and venous throm thrombosis
27. Surgical interventions for patients with non-ischemic dilated cardiomyopathy
28. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure
29. The angiotensin-converting enzyme gene polymorphism and responses to angiotensins and bradykinin in the human forearm
30. Left ventricular dilatation and the risk of congestive heart failure in people without myocardial infarction
31. Polymorphisms of the β-adrenergic receptor determine exercise capacity in patients with heart failure
32. The ACE gene and muscle performance
33. Association of a T29→C polymorphism of the transforming growth factor-β gene with genetic susceptibility to myocardial infarction in Japanese